Greetings From the Editor of Clinical Thyroidology

Abstract

Clinical Thyroidology®Vol. 35, No. 8 Greetings from the EditorFree AccessGreetings From the Editor of Clinical ThyroidologyPublished Online:16 Aug 2023https://doi.org/10.1089/ct.2023;35.305-306AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Greetings to our readers. I'm pleased to share this issue of Clinical Thyroidology, which begins with a review by Dr. Gary Francis, who summarizes a study on associations between free T3 levels and cardiometabolic events in children. Dr. Kenneth Burman provides his perspective on a study that evaluated levothyroxine formulation changes in the treatment of hypothyroidism. Related to this topic, Dr. Mayumi Endo discusses a study examining the trend of desiccated thyroid extract use in the United States. The issue also features a review by Dr. Giuseppe Barbesino of a study on the treatment of amiodarone-induced thyrotoxicosis and cardiovascular outcomes.On the topic of thyroid nodules and thyroid cancer, Drs. Erivelto Volpi and Jose Higino Steck summarizes a study reporting the preferences of patients and clinicians on the management of a cytologically indeterminate nodule. This is an appropriate introduction to the two parallel studies we review in this issue, by Drs. Anupam Kotwal and Whitney Goldner and by Giorgio Grani, on the updated performance characteristics of the Veracyte Afirma Genomic Sequencing Classifier and the Thyroseq (version 3) molecular tests, respectively. Drs. Terry Gao and Lindsay Kuo then provide their commentary on a study assessing shared decision-making between patients and clinicians on the management of low-risk differentiated thyroid cancers. The issue ends with an excellent summary by Dr. Theodora Pappa on a recently published phase 2 trial, on the redifferentiating role of trametinib in patients with metastatic radioactive iodine–refractory RAS-mutated differentiated thyroid cancers.I invite everyone to visit our various social media channels, where we recap the featured highlights from each month's issue and discuss other topics related to the latest clinical thyroid literature. All are welcome to join us at:Twitter:https://twitter.com/clinicalthyroid(@clinicalthyroid)Facebook:https://www.facebook.com/ThyroidAssociationLinkedIn:https://www.linkedin.com/company/american-thyroid-associationYoutube:https://www.youtube.com/user/thyroidorgI also thank the editorial board of Clinical Thyroidology for the Public [CTFP] (https://www.thyroid.org/patient-thyroid-information/ct-for-patients), as led by Dr. Alan Farwell, for their work in providing short summaries of our Clinical Thyroidology articles each month. These freely available, quicker reads are helpful to patients and to the general public who are interested in learning more about recently published studies in the clinical thyroid literature.We will continue to provide reviews, commentaries, editorials, and perspectives on the most relevant clinical thyroid studies from the published literature. Guidelines for submitting Letters to the Editor and select Guest Editorials that cover timely and innovative aspects of clinical thyroid disease management may be found at https://home.liebertpub.com/publications/clinical-thyroidologyand174/623/for-authors.Thank you again for your interest in Clinical Thyroidology. Please feel free to send me any questions or comments at [email protected].Warmest regards,Angela M. Leung, MD, MScEditor-in-Chief, Clinical ThyroidologyFiguresReferencesRelatedDetails Volume 35Issue 8Aug 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Greetings From the Editor of Clinical Thyroidology.Clinical Thyroidology®.Aug 2023.305-306.http://doi.org/10.1089/ct.2023;35.305-306Published in Volume: 35 Issue 8: August 16, 2023PDF download